Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | MAOA | P21397 | 6/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL443555 | 0.84 | MAOA (0.50) | MAPTCYP3A4MAOAKDM4EALDH1A1 | |
| SCHEMBL8543417 | 0.75 | MAOA (0.55) | MAPTCYP3A4MAOAKDM4EALDH1A1 | |
| SCHEMBL9550647 | 0.75 | MAPT (0.48) | MAPTCYP3A4MAOAKDM4EALDH1A1 | |
| SCHEMBL4571013 | 0.75 | CYP3A4 (1.00) | MAPTCYP3A4MAOAKDM4EALDH1A1 | |
| SCHEMBL22953335 | 0.75 | CYP3A4 (1.00) | MAPTCYP3A4MAOAKDM4EALDH1A1 | |
| SCHEMBL29924708 | 0.75 | MAPT (0.68) | MAPTCYP3A4MAOAKDM4EALDH1A1 | |
| SCHEMBL14481557 | 0.75 | MAPT (0.68) | MAPTCYP3A4MAOAKDM4EALDH1A1 | |
| SCHEMBL2594537 | 0.75 | MAPT (0.68) | MAPTCYP3A4MAOAKDM4EALDH1A1 | |
| SCHEMBL2138785 | 0.75 | CYP3A4 (1.00) | MAPTCYP3A4MAOAKDM4EALDH1A1 | |
| SCHEMBL29394312 | 0.75 | CYP3A4 (1.00) | MAPTCYP3A4MAOAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023240024-A1 | SULFAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | claimed |
| WO-2023240024-A1 | SULFAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-8747810-B2 | Compositions and methods for imaging tissues, organs and tumors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120269724-A1 | COMPOSITIONS AND METHODS FOR IMAGING TISSUES, ORGANS AND TUMORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-10-25 | — | — | US | disclosed |
| EP-2440584-A1 | COMPOSITIONS AND METHODS FOR IMAGING TISSUES, ORGANS AND TUMORS | President and Fellows of Harvard College (US) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010144891-A1 | COMPOSITIONS AND METHODS FOR IMAGING TISSUES, ORGANS AND TUMORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120269724-A1 | COMPOSITIONS AND METHODS FOR IMAGING TISSUES, ORGANS AND TUMORS | SSTR3, TACR1, SSTR5 | MAPT 3819/4885CYP3A4 4212/4885MAOA 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.